Abstract
Pharmacovigilance is vital for public health and patient safety and includes all activities relating to the detection, assessment and prevention of adverse effects due to medicinal products (see WHO 2004). Despite risk assessment before marketing authorisation, all medicines might produce adverse drug reactions (ADRs) during therapeutic use after marketing (Belton and the European Pharmacovigilance Research Group 1997).
Chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Belton, K. J. and the European Pharmacovigilance Group (1997). Attitude Survey of Adverse Drug-Reaction Reporting by Health Care Professionals across the European Union. European Journal of Pharmacology 52: 423-427.
Council of Europe (2009). The Ever-Growing Challenge of Medical Liability: National and European Responses. Strasbourg, 2-3 June 2009, Conference Proceedings.
Essinger, K. (2009). Medical Liability: Alternative Ways to Court Procedures. Council of Europe (ed) (2009). The Ever-Growing Challenge of Medical Liability: National and European Responses. Strasbourg, 2-3 June 2009, Conference Proceedings.
Romeo-Casabona, C. (2009). The Legal Approach to Medical Liability – Negligence and Breach of Patient’s Autonomy. Council of Europe (ed) (2009). The Ever-Growing Challenge of Medical Liability: National and European Responses. Strasbourg, 2-3 June 2009, Conference Proceedings.
Simon, J., Jansen, B. (2009). Economic Implications of Medical Liability Claims: Insurance and Compensation Schemes. Council of Europe (ed) (2009). The Ever-Growing Challenge of Medical Liability: National and European Responses. Strasbourg, 2-3 June 2009, Conference Proceedings.
WHO (2004). Pharmacovigilance: Ensuring the Safe Use of Medicines. WHO Policy Perspectives on Medicines 9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2017 The Author(s)
About this chapter
Cite this chapter
Kaeding, M., Schmälter, J., Klika, C. (2017). Conclusions and Recommendations. In: Pharmacovigilance in the European Union. Springer, Wiesbaden. https://doi.org/10.1007/978-3-658-17276-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-658-17276-3_7
Published:
Publisher Name: Springer, Wiesbaden
Print ISBN: 978-3-658-17275-6
Online ISBN: 978-3-658-17276-3
eBook Packages: Political Science and International StudiesPolitical Science and International Studies (R0)